- Home
- NRIX vs UPST Comparison
NRIX vs UPST Comparison
Compare NRIX & UPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIX | UPST |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | 357 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRIX | UPST |
|---|---|---|
| Price | $23.38 | $26.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $30.50 | ★ $45.84 |
| AVG Volume (30 Days) | 1.6M | ★ 3.6M |
| Earning Date | 04-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 131.25 |
| EPS | N/A | ★ N/A |
| Revenue | $76,987,000.00 | ★ $1,043,857,000.00 |
| Revenue This Year | N/A | $34.45 |
| Revenue Next Year | $48.05 | $32.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 99.31 | 63.99 |
| 52 Week Low | $8.20 | $23.97 |
| 52 Week High | $25.09 | $85.31 |
Technical Indicators
Market Signals| Indicator | NRIX | UPST |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 32.57 |
| Support Level | $14.63 | $25.18 |
| Resistance Level | $24.98 | $34.84 |
| Average True Range (ATR) | 1.21 | 1.62 |
| MACD | -0.26 | -0.65 |
| Stochastic Oscillator | 52.40 | 1.37 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).